DUAL AGONISTS OR COMBINATIONS Semaglutide is the post powerful of the GLP-1RAs currently available, but very powerful combinations of GLP-1RAs with other weight-regulating hormones and also monomolecular agonists with dual or triple action on the receptors for these hormones are now being introduced
In patients with type 2 diabetes receiving insulin, GLP-1 RA initiation may require insulin dose reduction to minimize hypoglycemia risk
Tighter oversight of manufacturers pricing policies and the competitive environment Its unseemly (polite word choice) that the CEO of Lilly, Dave Ricks, is able to rake in total compensation of $114 million in 2024 while at the same time acknowledging that the price his company charges for Zepbound is too high. Unseemly, because his payday was fueled by Lilly making more than $10 billion in profit from GLP-1s in 2024 alone
Gastrointestinal side effects and strict dietary adherence are potential barriers, particularly in long-term settings [160,161]
Martinez, R., et al
Images centred on the superficial layer of the TNC were captured under a 100 or 200 objective, and the immunoreactive cells in this region were counted with Image-Pro Plus
